Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Cash from Investing Activities (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Cash from Investing Activities for 11 consecutive years, with -$247.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities fell 45.07% year-over-year to -$247.4 million, compared with a TTM value of -$143.5 million through Dec 2025, up 59.39%, and an annual FY2025 reading of -$143.5 million, up 59.39% over the prior year.
  • Cash from Investing Activities was -$247.4 million for Q4 2025 at Spyre Therapeutics, down from $25.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $79.0 million in Q2 2025 and bottomed at -$247.4 million in Q4 2025.
  • Average Cash from Investing Activities over 5 years is -$28.5 million, with a median of $6.3 million recorded in 2021.
  • The sharpest move saw Cash from Investing Activities soared 801.33% in 2023, then crashed 1882.81% in 2024.
  • Year by year, Cash from Investing Activities stood at $9.7 million in 2021, then soared by 44.88% to $14.0 million in 2022, then plummeted by 351.94% to -$35.3 million in 2023, then crashed by 383.51% to -$170.5 million in 2024, then tumbled by 45.07% to -$247.4 million in 2025.
  • Business Quant data shows Cash from Investing Activities for SYRE at -$247.4 million in Q4 2025, $25.0 million in Q3 2025, and $79.0 million in Q2 2025.